DS-1103 / Daiichi Sankyo - LARVOL DELTA

Experimental evaluation of DC-DC buck converter based on adaptive fuzzy fast terminal synergetic controller. (PubMed, Sci Rep) - "Taking a switching DC-DC buck converter as a demonstration, the suggested AF-FTSC is thoroughly analyzed and executed on a dSPACE ds1103 controller board. The outcomes of the experiment confirm the competence and applicability of the suggested regulator."

Journal

Blockade of SIRPα-CD47 axis by anti-SIRPα antibody enhances anti-tumor activity of DXd antibody-drug conjugates. (PubMed, PLoS One) - "To this end, DS-1103a, a newly developed anti-human SIRPα antibody (Ab), was assessed for the potential combination benefit with datopotamab deruxtecan (Dato-DXd) and trastuzumab deruxtecan (T-DXd), DXd-ADCs targeting human trophoblast cell-surface antigen 2 and human epidermal growth factor receptor 2, respectively. Furthermore, in syngeneic mouse models, both Dato-DXd and T-DXd combination with anti-mSIRPα Ab showed stronger anti-tumor activity over the monotherapies. Taken together, this study provides a preclinical rationale of novel therapies for solid tumors combining SIRPα-CD47 blockers with DXd-ADCs."

Journal • Hematological Malignancies • Oncology • Solid Tumor • HER-2 • SIRPA

A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors (ESMO 2023) - P1 | "Primary endpoints include the safety and tolerability of the combination in both parts, determining the recommended dose of DS-1103a in combination for expansion in Part 1, and assessing the objective response rate in Part 2. Secondary endpoints include the antitumor activity of DS-1103a + T-DXd, pharmacokinetic profile of DS-1103a, and incidence of antidrug antibodies against DS-1103a."

Clinical • IO biomarker • Metastases • P1 data • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • SIRPA

Regulation of multi-area power system load frequency in presence of V2G scheme. (PubMed, PLoS One) - "To validate the outcomes of the simulation results, an experimental setup consisting of a real-time dSPACE DS1103 connected to another PC via QUARC pid_e data acquisition card was used. The experimental findings have substantiated the accuracy of the simulation findings about the superiority of the I+ECO+V2G methodology compared to both the I+ECO and I-control methodologies concerning system performance and LF control."

Journal

A Detailed dSPACE-Based Implementation of Modulated Model Predictive Control for AC Microgrids. (PubMed, Sensors (Basel)) - "All details of the implementation are given for establishing the dSPACE-based implementation of the control on a dSPACE ds1103 control platform, using MATLAB/Simulink for the controller design, I/O implementation and configuration with the embedded dSPACE's real-time interface in Simulink, and then using the ControlDesk software for monitoring and testing of the real plant. The latter consists of the VSI operating with LCL filters, and sharing an RL load with a paralleled VSI with exactly the same controller. Finally, the obtained experimental waveforms are shown, with our respective conclusions representing this work, which is a very valuable tool for helping microgrid researchers implement dSPACE-based real-time simulations."

Journal

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=78 | Recruiting | Sponsor: Daiichi Sankyo, Inc. | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Breast Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ER • PGR

Development of a quantitative systems pharmacology (QSP) model to support dose optimization of DS-1103a (anti SIRPa antibody) in combination with trastuzumab deruxtecan in patients with cancer. (ASCO 2023) - "The QSP model mechanistically characterized DS-1103a mechanism of action and linked PK to intratumoral RO and corresponding ADCP activity in both in vitro and in vivo setting. The model was used to derive the FIH starting dose and potentially clinically effective doses for DS-1103a in combination with T-DXd. This QSP model will be integrated into a large-scale disease platform to support dose expansion and further dose optimization as new clinical data emerge."

Clinical • Combination therapy • Oncology • CD47 • SIRPA

Adaptive frequency control in smart microgrid using controlled loads supported by real-time implementation. (PubMed, PLoS One) - "The MATLAB simulation results reveal that the suggested technique has a substantial advantage over other techniques in terms of frequency stability in the face of concurrent disturbances and parameter uncertainties. The real-time simulation tests are presented using a dSPACE DS1103 connected to another PC via QUARC pid_e data acquisition card and confirmed the MATLAB simulation results."

Journal

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=78 | Not yet recruiting | Sponsor: Daiichi Sankyo, Inc.

Combination therapy • Metastases • New P1 trial • Breast Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ER • PGR